Description
If you’re a biotech executive, investor, deal maker, entrepreneur, or adviser–or aspire to be one–then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. – Vetted benchmarks for key drivers of income, expenses, and valuation. – Proprietary analyses by Pharmagellan’s experienced consulting team. – More than 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you’re making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
